Biotech’s Latest: Heart Drug, ALS, Cancer Shifts
Kilder
- statnews.com: Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease - statnews.com
- biopharmadive.com: Cytokinetics heart drug scores in closely watched trial - BioPharma Dive
- biospace.com: Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update - BioSpace
- bioworld.com: Cytokinetics metrics satisfy in nHCM phase III - BioWorld News
- Biospace: QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS - BioSpace
- biospace.com: QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS - BioSpace
- Bioworld: Selective DNMT1 degrader shows potent anti-leukemic activity - BioWorld News
- bioworld.com: Selective DNMT1 degrader shows potent anti-leukemic activity - BioWorld News
- Fiercebiotech: Pfizer’s $2.3B Trillium bet ends in failure as remaining CD47 blocker scrapped along with T-cell engager - Fierce Biotech
- fiercebiotech.com: Pfizer’s $2.3B Trillium bet ends in failure as remaining CD47 blocker scrapped along with T-cell engager - Fierce Biotech
- biopharmadive.com: Cytospire hauls in $83M for a new type of T cell engager - BioPharma Dive
- news.google.com: Cytospire hauls in $83M for a new type of T cell engager - BioPharma Dive
- finance.yahoo.com: Cytospire hauls in $83M for a new type of T cell engager - Yahoo Finance
- Nature: Structure and druggable conformation of the homodimeric lipoprotein transporter of Acinetobacter baumannii - nature.com
- wikimedia: Photo by NIH Image Gallery from Bethesda, Maryland, USA / Wikimedia Commons / Public domain
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.